Consistent Double-Digit Revenue Growth
Amicus Therapeutics achieved its 17th consecutive quarter with double-digit sales growth in its core business, including a 22% increase in total revenue over the same period in 2024.
Galafold Patient Growth
Galafold delivered 13% year-over-year patient growth this quarter and is on track to achieve the highest number of global patient starts this year.
Strong Sales for Pombiliti and Opfolda
The second quarter marked the strongest commercial demand for Pombiliti and Opfolda since their launch, with revenue reaching $25.8 million, up 58% at constant exchange rates.
Strategic Partnerships and Pipeline Expansion
Amicus advanced its partnership with Dimerix for DMX-200, a first-in-class compound for a rare kidney disease, with the pivotal Phase III ACTION trial progressing well.
Positive Financial Outlook
The company is on track to achieve GAAP profitability in the second half of the year, with full-year 2025 financial guidance reaffirmed, including total revenue growth of 15% to 22%.